| 1482 |
National Cancer Institute |
Html |
en |
Thyroid Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of thyroid cancer. |
| NX Regional lymph | 0.514232 |
| differentiated thyroid carcinoma | 0.483242 |
| thyroid capsule | 0.458348 |
| lymph node recurrence | 0.424478 |
| lymph node involvement. | 0.433258 |
| thyroid carcinoma | 0.494127 |
| follicular thyroid carcinoma | 0.43746 |
| minimal extrathyroid extension | 0.497486 |
| papillary thyroid cancer | 0.500545 |
| recurrent differentiated thyroid | 0.423584 |
| perithyroid soft tissues | 0.49864 |
| M0 T2 Tumor | 0.418332 |
| N1a Metastases | 0.452974 |
| patients | 0.4225 |
| lymph node biopsy | 0.465877 |
| sentinel lymph node | 0.465511 |
| thyroid cancer. | 0.408942 |
| encases carotid artery | 0.459248 |
| lymph nodes | 0.70121 |
| papillary thyroid microcarcinomas | 0.421769 |
| papillary thyroid carcinoma | 0.467474 |
| prelaryngeal/Delphian lymph nodes | 0.599278 |
| T1b Tumor | 0.476542 |
| thyroid diseases | 0.408003 |
|
| T1a Tumor | 0.476741 |
| thyroid gland | 0.406975 |
| thyroid cancer | 0.570421 |
| mediastinal lymph nodes | 0.577558 |
| thyroid autoantibodies | 0.408316 |
| greatest dimension | 0.710356 |
| follicular thyroid cancer | 0.472046 |
| subcutaneous soft tissues | 0.453725 |
| soft tissues | 0.502801 |
| recurrent laryngeal nerve | 0.458581 |
| superior mediastinal lymph | 0.567495 |
| tumor suppressor gene | 0.41425 |
| regional lymph node | 0.969698 |
| distant metastasis | 0.429776 |
| TX Primary tumor | 0.476275 |
| cm | 0.593737 |
| primary tumor | 0.496822 |
| lymph node status | 0.43297 |
| differentiated thyroid cancer | 0.496492 |
| lymph node involvement | 0.43209 |
| M0 T1 Tumor | 0.448756 |
| tumor | 0.667722 |
| regional lymph nodes | 0.569893 |
| lymph node metastases | 0.446319 |
|
CLICK HERE |
| 1540 |
National Cancer Institute |
Html |
en |
Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies (PDQ®)–Health Professional Version |
Information about how to weigh the strength of the evidence obtained in human studies of integrative, alternative, and complementary therapies for cancer. |
| strength | 0.674769 |
| evidence score | 0.330764 |
| clinical details | 0.253336 |
| strongest endpoint | 0.346454 |
| weak study design | 0.389561 |
| PDQ cancer information | 0.609434 |
| PDQ information | 0.33766 |
| Best Case Series | 0.34796 |
| clinical trials | 0.245761 |
| cancer information summary | 0.520348 |
| human studies | 0.415104 |
| breast cancer prevention | 0.370124 |
| numeric scale | 0.249195 |
| randomized trial | 0.254175 |
| study types | 0.251887 |
| study design | 0.95862 |
| design categories yields | 0.398085 |
| NCI’s PDQ | 0.357199 |
| cancer treatment studies | 0.394746 |
| PDQ Adult Treatment | 0.532483 |
| NCI PDQ cancer | 0.476778 |
| weakest design | 0.286828 |
| statistical strength | 0.648901 |
| complementary therapies | 0.394252 |
| human cancer | 0.391957 |
|
| proper assessment | 0.249946 |
| Therapies Editorial Board | 0.336527 |
| PDQ Integrative | 0.333821 |
| strongest design | 0.2759 |
| different treatments | 0.250238 |
| clinical findings | 0.245005 |
| case series | 0.380662 |
| progressive alphabetic scale | 0.362349 |
| similar results | 0.25211 |
| therapeutic endpoint | 0.358766 |
| Cause-specific mortality | 0.243515 |
| endpoint | 0.41291 |
| individual case reports | 0.382311 |
| particular treatments | 0.266483 |
| total mortality | 0.246905 |
| scientific strength | 0.586275 |
| National Cancer Institute | 0.778424 |
| Editorial Board | 0.404104 |
| PDQ documents | 0.331784 |
| various types | 0.248384 |
| anecdotal reports | 0.254781 |
| cancer-related images | 0.244704 |
| tumor response | 0.253792 |
| stronger study design | 0.404144 |
|
CLICK HERE |
| 1556 |
National Cancer Institute |
Html |
en |
Colorectal Cancer Prevention (PDQ®)–Patient Version |
Expert-reviewed information summary about factors that may influence the risk of developing of colorectal cancer and about research aimed at the prevention of this disease. |
| cancer treatment | 0.462885 |
| cancer prevention trials | 0.5302 |
| colorectal cancer prevention | 0.614686 |
| colorectal polyps | 0.56189 |
| protective factors | 0.497455 |
| following PDQ summaries | 0.48755 |
| PDQ cancer information | 0.608246 |
| new colorectal cancers | 0.563344 |
| clinical trials | 0.59581 |
| possible harms | 0.498355 |
| increased risk | 0.474738 |
| cancer information summary | 0.540977 |
| risk factors | 0.560326 |
| breast cancer prevention | 0.482223 |
| colorectal cancer | 0.972144 |
| new colorectal cancer | 0.620653 |
| lower risk | 0.461958 |
| cancer patients | 0.460978 |
| nonpolyposis colon cancer | 0.4955 |
| cancer risk factor | 0.521529 |
| colon cancer prevention | 0.494063 |
| NCI’s PDQ | 0.461756 |
| Clinical Trials section | 0.458686 |
| smaller polyps lowers | 0.458496 |
|
| NCI PDQ cancer | 0.516757 |
| rectal cancer prevention | 0.488321 |
| large colorectal adenomas | 0.566232 |
| hormone replacement therapy | 0.492755 |
| familial adenomatous polyposis | 0.499723 |
| cancer risk factors | 0.517883 |
| colorectal adenomas | 0.616144 |
| cancer protective factor | 0.49566 |
| Cancer Information Service | 0.487513 |
| prevention clinical trials | 0.487754 |
| Prevention Editorial Board | 0.488084 |
| treatment clinical trials | 0.458488 |
| National Cancer Institute | 0.559763 |
| cancer doctors | 0.458093 |
| colorectal cancer cases | 0.619218 |
| colon cancer | 0.508406 |
| Cancer Care page | 0.480229 |
| PDQ database | 0.45787 |
| PDQ summary | 0.478855 |
| invasive colorectal cancer | 0.6296 |
| cancer clinical trials | 0.495703 |
| cancer information summaries | 0.492581 |
| comprehensive cancer information | 0.492387 |
| risk | 0.615513 |
|
CLICK HERE |
| 1582 |
National Cancer Institute |
Html |
en |
Adult Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version |
Soft tissue sarcomas can form almost anywhere in the body, but are most common in the head, neck, arms, legs, truck, and abdomen. Find out about risk and genetic factors, symptoms, tests to diagnose, prognosis, staging, and treatment for soft tissue sarcoma. |
| cancer treatment | 0.262443 |
| malignant tumor cells | 0.254786 |
| cancer spreads | 0.245112 |
| body | 0.294182 |
| type | 0.25634 |
| PDQ cancer information | 0.274383 |
| clinical trial search | 0.274958 |
| clinical trials | 0.461076 |
| nearby lymph nodes | 0.239706 |
| cancer information summary | 0.260539 |
| clinical trial | 0.328582 |
| patients | 0.25186 |
| blood vessels | 0.240907 |
| treatment clinical trial | 0.238552 |
| subcutaneous tissue | 0.292398 |
| NCI PDQ cancer | 0.240642 |
| Treatment Option Overview | 0.242732 |
| lymph nodes | 0.261315 |
| radiation therapy | 0.391981 |
| little normal tissue | 0.262689 |
| soft tissue sarcoma | 0.92025 |
| General information | 0.241563 |
| treatment | 0.357792 |
| wide local excision | 0.284219 |
| nearby healthy tissue | 0.249677 |
|
| NCI-supported cancer | 0.247977 |
| cancer cells | 0.331726 |
| laboratory test | 0.23958 |
| soft tissues | 0.24063 |
| connective tissue | 0.264853 |
| treatment clinical trials | 0.254055 |
| National Cancer Institute | 0.283258 |
| soft tissue sarcomas | 0.301359 |
| new treatment | 0.260355 |
| adult soft tissue | 0.678017 |
| tissue sarcoma cells | 0.278793 |
| external radiation therapy | 0.248848 |
| primary tumor | 0.244329 |
| metastatic tumor | 0.239026 |
| tissue samples | 0.246374 |
| Regional hyperthermia therapy | 0.239395 |
| cancer clinical trials | 0.280749 |
| stage | 0.259627 |
| tumor | 0.3265 |
| Tissue Sarcoma Treatment | 0.274121 |
| treatment options | 0.240625 |
| internal radiation therapy | 0.238752 |
| cancer | 0.489567 |
| information | 0.283228 |
|
CLICK HERE |
| 1743 |
National Cancer Institute |
Html |
en |
Photodynamic Therapy for Cancer |
A fact sheet that explains photodynamic therapy, how it is administered, and indications and side effects of treatment. |
| cancer treatment | 0.467161 |
| skin cancer | 0.463524 |
| agent | 0.509208 |
| necessary nutrients | 0.453814 |
| blood cancers | 0.455343 |
| activating light | 0.500969 |
| cutaneous T-cell lymphoma | 0.497644 |
| surface tumors | 0.462582 |
| body | 0.47526 |
| different areas | 0.455534 |
| light sources | 0.464075 |
| healthy tissue | 0.483908 |
| bright indoor light | 0.598285 |
| U.S. Food | 0.516598 |
| specific wavelength | 0.502289 |
| certain cancers | 0.465708 |
| patients | 0.455008 |
| blood cells | 0.468142 |
| photosensitizing agent | 0.45652 |
| non-small cell lung | 0.667463 |
| photosensitizer | 0.466135 |
| symptoms | 0.456503 |
| particular type | 0.455996 |
| direct sunlight | 0.514024 |
| specific type | 0.457687 |
|
| treatment | 0.479989 |
| esophageal cancer | 0.492936 |
| photodynamic therapy | 0.576544 |
| nearby healthy tissue | 0.481898 |
| skin | 0.463697 |
| Drug Administration | 0.510947 |
| active form | 0.454418 |
| cancer cells | 0.690083 |
| fiber optic cable | 0.49481 |
| Barrett esophagus | 0.454031 |
| photosensitizers | 0.460437 |
| tumor cells | 0.475849 |
| normal cells | 0.508255 |
| PDT | 0.970829 |
| Extracorporeal photopheresis | 0.455159 |
| large tumors | 0.503661 |
| porfimer sodium | 0.78695 |
| fiber optic cables | 0.493403 |
| light-emitting diodes | 0.456906 |
| nearby cells | 0.473123 |
| tumors | 0.505296 |
| Laser light | 0.464403 |
| cell lung cancer | 0.646935 |
| nearby cancer cells | 0.527607 |
|
CLICK HERE |
| 1775 |
National Cancer Institute |
Html |
es |
Náuseas y vómitos relacionados con el tratamiento (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las náuseas y los vómitos como complicaciones a causa del cáncer o su tratamiento. Se describen abordajes de tratamiento de las náuseas y los vómitos. |
| chemotherapy induced nausea | 0.342573 |
| conditioned nausea | 0.336948 |
| Bouganim N | 0.33134 |
| delayed chemotherapy-induced nausea | 0.334556 |
| anticipatory nausea | 0.772561 |
| schwartzberg ls | 0.356266 |
| horas vo | 0.591535 |
| Krozely MG | 0.34156 |
| Hesketh PJ | 0.353455 |
| colorectal cancer | 0.336446 |
| chemotherapy-induced nausea | 0.951327 |
| dosis vo | 0.347133 |
| continuación presente nva | 0.332752 |
| mg vr | 0.340801 |
| community clinical practices | 0.338332 |
| anticipatory emesis | 0.337674 |
| cancer chemotherapy | 0.773091 |
| Pain Symptom Manage | 0.361458 |
| Support Oncol | 0.346357 |
| quimioterapia categorÃa | 0.357422 |
| Roscoe JA | 0.415752 |
| NyV agudos | 0.347107 |
| mg im | 0.432997 |
| NVIQ agudos | 0.337444 |
| controlling chemotherapy-induced nausea | 0.364663 |
|
| delayed nausea | 0.337245 |
| Care Cancer | 0.464148 |
| Bovbjerg DH | 0.349781 |
| VO Inhibidor | 0.357448 |
| mg vo | 0.767769 |
| quimioterapia vo | 0.485969 |
| Kris MG | 0.406292 |
| quimioterapia vo la | 0.389831 |
| significant clinical problem | 0.339573 |
| Prospective validation | 0.334589 |
| Consult Clin Psychol | 0.417355 |
| clinical oncology | 0.347599 |
| quimioterapia iv | 0.373245 |
| Hickok JT | 0.353347 |
| dÃas vo inhibidor | 0.344362 |
| chemotherapy patients | 0.331687 |
| Clin Oncol | 0.384683 |
| sistema nervioso central | 0.357893 |
| patients treated | 0.340656 |
| dÃas vo | 0.360421 |
| Morrow GR | 0.513036 |
| potencial emetógeno | 0.502334 |
| Clinical roundtable monograph | 0.340704 |
| Adv Hematol Oncol | 0.339165 |
|
CLICK HERE |
| 1811 |
National Cancer Institute |
Html |
es |
Descripción del tratamiento de tumores de encéfalo y de médula espinal infantiles (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de varios tumores de encéfalo infantiles. |
| Altekruse SF | 0.447856 |
| American Academy | 0.440446 |
| Brain Tumor Registry | 0.477956 |
| pediatric cancer | 0.464838 |
| plexo coroideo | 0.50432 |
| largo plazo | 0.465315 |
| cancer center | 0.498759 |
| Children's National Health | 0.432864 |
| Declining childhood | 0.43143 |
| astrocitomas pilocÃticos | 0.47055 |
| Instituto Nacional | 0.460068 |
| Reifenberger G | 0.447846 |
| World Health Organization | 0.488687 |
| Health Organization Classification | 0.496391 |
| Pediatric Brain Tumor | 0.46738 |
| tumor embrionario | 0.530794 |
| SAI Tratamiento | 0.438882 |
| tumores glioneuronales papilares | 0.533183 |
| Children's Oncology Group | 0.486579 |
| Childhood Cancer Survivor | 0.446412 |
| SNC primarios | 0.433523 |
| central nervous system | 0.795553 |
| pdq correspondiente tipo | 0.466293 |
| Smith MA | 0.441598 |
| Acta Neuropathol | 0.450438 |
|
| long-term survivors | 0.443577 |
| tumores papilares | 0.526133 |
| Organización Mundial | 0.435085 |
| United States | 0.447735 |
| subtipo patológico sumario | 0.46642 |
| Neuro Oncol | 0.509938 |
| PDQ Descripción | 0.456005 |
| Pediatr Blood Cancer | 0.436965 |
| PDQ Efectos tardÃos | 0.580122 |
| National Cancer Institute | 0.479004 |
| Pollack IF | 0.449126 |
| tumor atÃpico | 0.44433 |
| Clin Oncol | 0.579132 |
| nervous system tumors | 0.447762 |
| sistema nervioso central | 0.82435 |
| childhood brain tumors | 0.461864 |
| brain tumor | 0.932348 |
| Kimmel Comprehensive Cancer | 0.433441 |
| Perry A | 0.444221 |
| tumores embrionarios | 0.61933 |
| newly diagnosed | 0.441805 |
| espinal infantiles recién | 0.46155 |
| childhood central nervous | 0.442376 |
| Wilmot Cancer Center | 0.432289 |
|
CLICK HERE |
| 1982 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de tiroides (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de tiroides. |
| glándula tiroides | 0.908295 |
| estadios iva | 0.233602 |
| siguientes procedimientos | 0.206098 |
| ganglios linfáticos.ampliar cáncer | 0.716308 |
| hormona tiroidea | 0.292738 |
| radioterapia intraoperatoria | 0.215525 |
| siguientes aspectos | 0.243621 |
| menos.ampliar cáncer | 0.315655 |
| gen ret | 0.208945 |
| estadio ii | 0.465746 |
| enfermedad tiroidea | 0.223963 |
| ganglio linfático centinela | 0.278708 |
| vÃa oral | 0.205075 |
| rayos x | 0.221349 |
| estadio ivb | 0.462997 |
| estadio ivc | 0.408027 |
| enlace drugs approved | 0.226007 |
| ondas sonoras | 0.222594 |
| estadio iva | 0.373015 |
| órgano fonador | 0.446375 |
| National Cancer Institute | 0.204974 |
|
| tiroides causa efectos | 0.252932 |
| endocrina múltiple tipo | 0.287058 |
| hormonas tiroideas | 0.209751 |
| Instituto Nacional | 0.209158 |
| PDQ Tratamiento | 0.229219 |
| antecedentes familiares | 0.2071 |
| pacientes pastillas | 0.209381 |
| siguientes funciones | 0.210244 |
| Physician Data Query | 0.218087 |
| estadio iii | 0.401226 |
| centÃmetros.ampliar cáncer | 0.275936 |
| suficiente hormona tiroidea | 0.209562 |
| nódulo tiroideo | 0.292185 |
| Thyroid Cancer | 0.21393 |
| hormona calcitonina | 0.209835 |
| pequeña dosis | 0.204395 |
| pequeña parte | 0.2042 |
| células tiroideas | 0.225287 |
| cuerpo.ampliar cáncer | 0.277585 |
| nódulos tiroideos | 0.301973 |
| tiroides.ampliar cáncer | 0.26979 |
|
CLICK HERE |
| 3426 |
National Cancer Institute |
Html |
es |
El uso de la hipertermia en el tratamiento del cáncer |
Hoja informativa que explica en qué consiste la hipertermia (el tratamiento de los tumores con altas temperaturas) y sus efectos secundarios. |
| Lippincott Williams | 0.53777 |
| Lancet Oncology | 0.561914 |
| Gunderson LL | 0.539005 |
| Bast RC Jr | 0.559948 |
| Hildebrandt B | 0.608355 |
| Zee J | 0.537016 |
| undergoing surgical debulking | 0.565384 |
| causa efectos | 0.537555 |
| Gibbs FA Jr | 0.56087 |
| molecular basis | 0.53797 |
| intraperitoneal chemotherapy | 0.537405 |
| DeVita VT Jr | 0.563586 |
| termómetros minúsculos | 0.539825 |
| Kufe DW | 0.535758 |
| Kapp DS | 0.536798 |
| PubMed Abstract | 0.959153 |
| general medicamentos | 0.53615 |
| numerosos estudios | 0.552283 |
| Clinical Oncology | 0.559745 |
| Tepper JE | 0.538345 |
| International Journal | 0.535346 |
| Critical Reviews | 0.540202 |
| Isolation perfusion | 0.539903 |
| perfusión peritoneal hipertérmica | 0.626548 |
| hyperthermic peritoneal perfusion | 0.599527 |
|
| Pingpank JF | 0.537893 |
| numerosos obstáculos | 0.535929 |
| Libutti SK | 0.60375 |
| Carlson RW | 0.535964 |
| Wust P | 0.612473 |
| Decker Inc | 0.534795 |
| consecuencia quemaduras | 0.537822 |
| Issels RD | 0.537803 |
| combined treatment | 0.542204 |
| inserta pequeñas agujas | 0.572325 |
| también llamada terapia | 0.570859 |
| Churchill Livingstone | 0.537458 |
| Hellman S | 0.534905 |
| malignant peritoneal mesothelioma | 0.597049 |
| promising approach | 0.54123 |
| 6th ed | 0.538756 |
| cuello uterino | 0.631745 |
| Alexander HR | 0.602298 |
| Clinical Radiation Oncology | 0.587129 |
| altas temperaturas | 0.793884 |
| Ahlers O | 0.540177 |
| Hahn GM | 0.536167 |
| Roemer RB | 0.538179 |
| Sreenivasa G | 0.536365 |
|
CLICK HERE |
| 15648 |
National Cancer Institute |
Html |
en |
NCI Grant Policies |
Research grants are subject to a variety of policy requirements. Find highlights of policy announcements or changes specific to NCI. |
| Large R01s | 0.450134 |
| intramural investigators | 0.495879 |
| P01 renewal applications | 0.616984 |
| comprehensive access | 0.459855 |
| research grants | 0.682427 |
| specific policy | 0.488359 |
| evidence-based approaches | 0.457301 |
| human health | 0.466536 |
| Access Policy | 0.490853 |
| cancer therapy | 0.46631 |
| budget request | 0.487575 |
| prior approval | 0.46826 |
| clinical trials | 0.978226 |
| alternative calculation | 0.447591 |
| NIH Grants Policy | 0.785706 |
| additional information | 0.464918 |
| unsolicited R01 applications | 0.694664 |
| exceptions | 0.333503 |
| NIH GDS policy | 0.707591 |
| cooperative agreements | 0.455552 |
| research results | 0.500906 |
| direct cost requests | 0.569063 |
| PARs | 0.332254 |
| grants administration policies | 0.684335 |
| cancer research continuum | 0.601742 |
|
| NCI-Supported Interventional Clinical | 0.650424 |
| non-NIH funded investigators | 0.630213 |
| NIH research | 0.564712 |
| contracts | 0.352239 |
| large R01 payline | 0.833282 |
| NCI Clinical Trials | 0.784254 |
| genomic research data | 0.651702 |
| final results | 0.607682 |
| general R01 payline | 0.832292 |
| NCI Program Director | 0.732659 |
| Scientific Review | 0.449688 |
| budget format | 0.487382 |
| grantees | 0.329888 |
| NIH Guide | 0.534988 |
| interventional clinical trials | 0.88994 |
| deviation | 0.332851 |
| directly impact patient | 0.587395 |
| policy announcements | 0.520246 |
| Type | 0.343808 |
| policy requirements | 0.522004 |
| separate NCI payline | 0.844339 |
| interventional cancer research | 0.663219 |
| prior project period | 0.601145 |
| direct cost budget | 0.622892 |
|
CLICK HERE |